DDInter456 DDInter1376
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Cyclophosphamide {u} (Compound) resembles {v} (Compound) Mechlorethamine
Cyclophosphamide {u} (Compound) binds {v} (Gene) CYP3A4
Cyclophosphamide {u} (Compound) downregulates {v} (Gene) ENOPH1
Cyclophosphamide {u} (Compound) causes {v} (Side Effect) Impaired healing
Cyclophosphamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Cyclophosphamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Peginterferon alfa-2a
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mitomycin
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Cyclophosphamide {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Cyclophosphamide {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Cyclophosphamide (Compound) resembles Mechlorethamine (Compound)
Cyclophosphamide (Compound) binds CYP3A4 (Gene)
Cyclophosphamide (Compound) downregulates ENOPH1 (Gene)
Cyclophosphamide (Compound) causes Impaired healing (Side Effect)
Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Modafinil
Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Peginterferon alfa-2a
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Cyclophosphamide may lead to a major life threatening interaction when taken with Golimumab
Cyclophosphamide may lead to a major life threatening interaction when taken with Cladribine